BeStock  
Stocks › Biotechnology › MLYS

Mineralys Therapeutics MLYS

US equityMarket cap rank #2754Biotechnology
$23.30 −$0.33 (-1.40%)
Pre-market · Oct 6, 4:10 am ET · After hours $23.40 +0.43%
Open$23.98
Prev close$23.63
Day range$22.97 – $24.00
Volume1.08M
Market cap$2.06B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: ANNUAL, ended Dec 2025

Revenue$0.00
Operating profit-$170.60M+11.3% YoY
Net profit-$154.65M+13.0% YoY
Diluted EPS-$2.29+37.4% YoY

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Liabilities / assets17.5%
Cash & investments$661.41M
Net cash (debt)$661.41M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 Q4 2025 Q3 2025 Q2
Total Non-Current Assets $2.05M $392,000.00 $420,000.00 $151,000.00 $455,000.00
Other Non-Current Assets $2.02M $360,000.00 $382,000.00 $144,000.00 $433,000.00
Net PPE $27,000.00 $32,000.00 $38,000.00 $7,000.00 $22,000.00
Retained Earnings -$737.58M -$496.51M -$457.17M -$424.94M -$388.00M
Other Current Assets $4.39M $6.41M $4.75M $6.17M $10.35M
-Short Term Investments $523.14M $533.28M $483.71M $376.03M $223.13M
-Cash and Cash Equivalents $138.27M $112.78M $172.92M $217.60M $101.79M
Cash and Cash Equivalents & Short-Term Investments $661.41M $646.06M $656.64M $593.63M $324.92M
Total Current Assets $665.80M $652.47M $661.39M $599.80M $335.27M
Total Assets $667.85M $652.86M $661.81M $599.95M $335.72M
Total Liabilities $116.94M $14.72M $15.11M $23.52M $22.17M
Total Current Liabilities $19.32M $14.72M $15.11M $23.52M $22.17M
Additional Paid-In Capital $1.29B $1.13B $1.10B $1.00B $701.55M
-Common Stock $9,000.00 $8,000.00 $8,000.00 $8,000.00 $6,000.00
Capital Stock $9,000.00 $8,000.00 $8,000.00 $8,000.00 $6,000.00
Stockholders' Equity $550.92M $638.14M $646.69M $576.43M $313.55M
Total Equity $550.92M $638.14M $646.69M $576.43M $313.55M
Total Non-Current Liabilities $97.62M $0.00 $0.00 $0.00 $0.00
Current Accrued Expenses $14.06M $11.29M $7.56M $18.52M $16.39M
-Accounts Payable $1.07M $1.12M $2.02M $1.12M $3.16M
Payables $1.07M $1.12M $2.02M $1.12M $3.16M

Income statement

Line item 2025 ANNUAL 2024 ANNUAL 2023 ANNUAL 2022 ANNUAL 2021 ANNUAL
Research & Development $132.01M $168.58M $70.36M $26.25M $16.31M
-General & Admin Expense $38.60M $23.82M $14.30M $5.23M $2.42M
Selling and Admin Expenses $38.60M $23.82M $14.30M $5.23M $2.42M
Operating Expense $170.60M $192.40M $84.66M $31.48M $18.73M
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Diluted EPS -$2.29 -$3.66 -$1.99 -$0.76 -$3.77
Operating Profit -$170.60M -$192.40M -$84.66M -$31.48M -$18.73M
Net Non-Operating Interest Income (Expense) $15.95M $14.59M $12.76M $1.68M -$27,000.00
Non-Operating Interest Income $15.95M $14.59M $12.76M $1.68M –
Pretax Profit -$154.65M -$177.81M -$71.90M -$29.80M -$19.41M
Net Profit -$154.65M -$177.81M -$71.90M -$29.80M -$19.41M
Profit from Continuing Operations -$154.65M -$177.81M -$71.90M -$29.80M -$19.41M
Net Income to Parent Company -$154.65M -$177.81M -$71.90M -$29.80M -$19.41M
Net Income to Common Stockholders -$154.65M -$177.81M -$71.90M -$29.80M -$19.41M
Basic EPS -$2.29 -$3.66 -$1.99 -$0.76 -$3.77
Other Income (Expense) – $5,000.00 $3,000.00 $4,000.00 -$656,000.00
Other Non-Operating Income (Expenses) – $5,000.00 $3,000.00 $4,000.00 $1,000.00
Non-Operating Interest Expense – – – – $27,000.00
Gain on Sale of Security – – – – -$657,000.00

Discussion

No comments yet — be the first to weigh in on MLYS.

Leave a comment

Scroll to Top